In the last trading session, 3.8 million Regulus Therapeutics Inc (NASDAQ:RGLS) shares changed hands as the company’s beta touched 1.45. With the company’s per share price at $1.34 changed hands at $0.11 or 8.94% during last session, the market valuation stood at $87.78M. RGLS’s last price was a discount, traded about -182.84% off its 52-week high of $3.79. The share price had its 52-week low at $0.83, which suggests the last value was 38.06% up since then. When we look at Regulus Therapeutics Inc’s average trading volume, we note the 10-day average is 0.93 million shares, with the 3-month average coming to 419.21K.
Analysts gave the Regulus Therapeutics Inc (RGLS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.33. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended RGLS as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Regulus Therapeutics Inc’s EPS for the current quarter is expected to be -0.22.
Regulus Therapeutics Inc (NASDAQ:RGLS) trade information
Instantly RGLS was in green as seen at the end of in last trading. With action 14.53%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -15.19%, with the 5-day performance at 14.53% in the green. However, in the 30-day time frame, Regulus Therapeutics Inc (NASDAQ:RGLS) is -14.10% down. Looking at the short shares, we see there were 1.76 million shares sold at short interest cover period of 5.51 days.
Regulus Therapeutics Inc (RGLS) estimates and forecasts
Data shows that the Regulus Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -14.65% over the past 6 months, a 44.30% in annual growth rate that is considerably higher than the industry average of 17.30%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 50.96%. The 2025 estimates are for Regulus Therapeutics Inc earnings to increase by 46.10%, but the outlook for the next 5-year period is at -0.36% per year.
RGLS Dividends
Regulus Therapeutics Inc is expected to release its next quarterly earnings report in March.
Regulus Therapeutics Inc (NASDAQ:RGLS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.26% of Regulus Therapeutics Inc shares while 88.28% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 90.32%. There are 88.28% institutions holding the Regulus Therapeutics Inc stock share, with FEDERATED HERMES, INC. the top institutional holder. As of 2024-06-30, the company held 19.9374% of the shares, roughly 12.85 million RGLS shares worth $22.94 million.
RA CAPITAL MANAGEMENT, L.P. holds the second largest percentage of outstanding shares, with 9.6952% or 6.25 million shares worth $11.16 million as of 2024-06-30.
Among Mutual Funds, the top two as of Oct 31, 2024 were Federated Hermes Kaufmann Fund and Vanguard Total Stock Market Index Fund. With 7.88 shares estimated at $10.56 million under it, the former controlled 12.03% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 3.82% of the shares, roughly 2.5 shares worth around $3.35 million.
